Home>Topics>Stocks>Biomed Realty Trust

Biomed Realty Trust BMR

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Biomed Realty Trust declares $0.25 dividend

      Headlines

      Tue, 16 Sep 2014

      BioMed Realty Trust (NYSE: BMR ) declares $0.25/share quarterly dividend , in line with previous. Forward yield 4.71% Payable Oct. 15; for shareholders of record Sept. 30; ex-div Sept. 26. Post your comment!

    2. Dropping Coverage of BioMed Realty Trust

      Commentary

      Fri, 13 Jun 2014

      We are dropping coverage of BioMed Realty Trust . We cover a selection of roughly 1,500 stocks and adjust our coverage as necessary based on client demand and investor interest.

    3. Maintaining Our View on BioMed Realty Trust Following First-Quarter Results

      Commentary

      Thu, 1 May 2014

      A number of moving parts influenced year-over-year comparisons in life-science landlord BioMed's first-quarter results, but overall results are tracking near our expectations, and we're maintaining both our $20 fair value estimate and our no-moat rating for the firm. For the quarter, on a ...

    4. We Remain Cautious on BioMed Following Mixed 4Q Results; Maintaining $20 Fair Value Estimate

      Commentary

      Thu, 6 Feb 2014

      Lab and research space landlord BioMed Realty Trust reported fourth-quarter results that were near our expectations. We're maintaining both our $20 fair value estimate and no

    5. New Morningstar Analyst Report for BioMed Realty Trust Inc

      Stock Reports

      Fri, 20 Dec 2013

      Many of BioMed's tenants lack proven, long-term revenue streams and are instead reliant upon investment capital for early-stage development expenses. Relative to regular office properties, life sciences real estate involves specialized infrastructure. If demand for life science space falls, it's

    6. BioMed's Per-Share Metrics Fail to Live Up to Reported Headline Growth; Maintaining $20 Fair Value

      Commentary

      Wed, 6 Nov 2013

      Life sciences landlord BioMed Realty Trust reported solid headline growth due largely to its recent acquisition of Wexford's portfolio, but after accounting for incremental

    7. Josh M* trades today

      Commentary

      Fri, 31 May 2013

      Hi folks, Josh just sold off BMR , WM and WR He also bought GSK, RCI and SO. Thought on these moves? I already sold WR a couple months ago and never held BMR or WM. Now I am looking at his buys. SO looks like a very solid

    8. We Have Lowered BioMed's Moat Rating to None From Narrow

      Commentary

      Mon, 22 Apr 2013

      We are lowering our moat rating for BioMed Realty Trust BMR to none from narrow, because of higher estimated property maintenance expenditures. Incorporating higher property maintenance

    9. BioMed Under Review

      Commentary

      Thu, 4 Apr 2013

      We are placing BioMed Realty Trust BMR under review as we transfer coverage to a new analyst.

    10. BioMed Acquires Wexford; Deal is Value-Neutral, but Pressures Overall Returns

      Commentary

      Tue, 26 Mar 2013

      We are maintaining our $21 fair value estimate and narrow moat rating for BioMed Realty Trust BMR following its $640 million acquisition of privately held life sciences real estate peer Wexford Science & Technology. Although

    « Prev1234Next »
    Content Partners